Experimental Drug Retatrutide Shows Up to 30% Weight Loss in Phase 3 Trial
सिर्फ तथ्य

Experimental Drug Retatrutide Shows Up to 30% Weight Loss in Phase 3 Trial

सारांश

In a large phase-3 study, the weekly injection retatrutide led to an average weight loss of 25% after 80 weeks at its highest dose, with additional reductions in knee pain and sleep-apnea events.

A phase-3 trial involving 2,339 adults with obesity but without diabetes found that the experimental weekly injection retatrutide produced substantial weight loss and improvements in related health issues. Participants received weekly doses of 4, 9 or 12 milligrams, or a placebo, in a double-blind design.

After 80 weeks, average weight reductions were 17.6% for the 4-mg group, 23.7% for the 9-mg group and 25% for the 12-mg group, compared with a 3.9% loss in the placebo arm. An extension study of 532 participants who continued the highest dose for an additional 24 weeks showed average weight loss of 29.9% after 104 weeks; statistical modeling estimated a loss of about 30% when treatment was uninterrupted.

The trial also reported secondary benefits. Among 574 participants with knee osteoarthritis, pain scores fell by 4.1 points on a 0-10 scale in the 12-mg group versus 2.5 points with placebo. In 243 participants with obstructive sleep apnea, the highest dose reduced apnea events by an average of 32.1 episodes per hour, compared with 9.6 episodes in the placebo group.

Gastrointestinal side effects were the most common adverse events, affecting roughly 42% of participants at the highest dose, primarily during dose escalation. Treatment discontinuation due to adverse events occurred in 11% of the 12-mg group versus 4.6% of placebo recipients. Serious adverse events were reported in 10.5% of the high-dose group and 5.5% of the placebo group, though causality was not established.

The study, published in The New England Journal of Medicine, was funded and data-managed by Eli Lilly, the drug’s manufacturer. Researchers noted that the trial was not designed to assess cardiovascular safety and did not directly compare retatrutide with existing obesity medications such as semaglutide or tirzepatide.

स्रोत

ScienceAlert

पहली बार यहां रिपोर्ट किया गया

पढ़ते रहें — निःशुल्क

समाचार फ़ॉलो करने के लिए मुफ़्त खाता बनाएँ। कार्ड की आवश्यकता नहीं।